logo-loader

Destiny Pharma to build on progress made by two key assets

Published: 07:56 09 Sep 2021 BST

Destiny Pharma PLC -

Destiny Pharma PLC (AIM:DEST) hailed the progress made with its two lead assets.

In an update alongside interim results, it said a phase III evaluation of the NTCD-M3 programme targeting C. difficile (CDI (NYSE:CDI)) is on track to begin in the second half of next year.

“As we finalise the phase III study design and network with CDI (NYSE:CDI) medical experts, we are increasingly enthused by the positioning of NTCD-M3 as a single strain, natural biotherapeutic and its great potential in a large market where peak global product sales could reach US$1bn,” the clinical stage, innovative biotechnology company told investors.

Discussions are progressing around the study design for its XF-73 nasal gel for the prevention of post-surgical infections, the company added.

“We are very pleased with the quality of the XF-73 nasal phase IIb data and are now focused on clarifying the phase III trial designs in the US and Europe,” Destiny said.

“We are confident that XF-73 has the potential to deliver a major improvement in the prevention of post-surgical infections caused by Staphylococcus aureus.”

The innovation meets a “clear clinical need” and therefore has blockbuster potential. It believes peak annual sales could be US$1bn in the US alone, the statement said.

Cash resources stood at £7.1mln, enough to fund it to the final quarter of next year.

It posted a loss of almost £3mln due to investment in R&D.

Destiny Pharma's nasal spray project already delivering "more than hoped for"

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than hoped for" and...

on 2/5/23